ONC updates approved test methods

| | Health Exec | Policy & Regulations

The Office of the National Coordinator for Health Information Technology (ONC) has released an update of its approved test methods for clinical quality measures under the 2014 Edition of the Meaningful Use program.

The 2014 Edition includes Stage 2 criteria and several changes to requirements in Stage 1. The update aligns test methods with a new version of the Cypress open source certification testing tool for capturing, calculating and reporting clinical quality measures under Stage 2. Updates also are available for the National Institute of Standards and Technology Transport Test Tool used with the test methods, also called procedures.

More information is available on the ONC 2014 Testing and Certification Web site, including a list of test methods with specific certification criteria numbers and links to test data. “If there is no test data link, the test data are either not required or supplied by the vendor,” according to ONC.

 

Related Content

Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
10 signs AI is ‘eating the world (of venture capital)’
Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.